Technical Analysis for AQST - Aquestive Therapeutics, Inc.

Grade Last Price % Change Price Change
grade D 7.98 1.14% 0.09
AQST closed up 1.14 percent on Thursday, December 13, 2018, on 1.15 times normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong N/A Down Down
See historical AQST trend table...

Date Alert Name Type % Chg
Dec 13 Spinning Top Other 0.00%
Dec 13 Narrow Range Bar Range Contraction 0.00%
Dec 13 NR7 Range Contraction 0.00%
Dec 13 Wide Bands Range Expansion 0.00%
Dec 13 Oversold Stochastic Weakness 0.00%
Dec 12 Wide Bands Range Expansion 1.14%
Dec 12 Oversold Stochastic Weakness 1.14%
Dec 11 NR7 Range Contraction -6.99%
Dec 11 Wide Bands Range Expansion -6.99%
Dec 11 Oversold Stochastic Weakness -6.99%

Older signals for AQST ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Aquestive Therapeutics, Inc. is a specialty pharmaceutical company. The Company is focused on the development of treatments for diseases related to the central nervous system (CNS). Its CNS programs consist of a pipeline of products that include Libervant, Sympazan, and AQST-117. Libervant is a buccal soluble film formulation of diazepam for the treatment of recurrent epileptic seizures. Sympazan is an oral soluble film formulation of clobazam for the treatment of seizures associated with a rare, intractable form of epilepsy known as Lennox-Gastaut Syndrome. AQST-117 is an oral soluble film formulation of riluzole for the treatment of Amyotrophic Lateral Sclerosis. The Company’s complex molecule programs consist of AQST-108, and AQST-305, for the treatment of anaphylaxis and neuroendocrine tumors respectively. The Company also has a pipeline of products under partner programs, which includes Suboxone and APL-130277 for the treatment of opioid dependence, and Parkinson’s disease.
Is AQST a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 20.7
52 Week Low 7.47
Average Volume 115,301
200-Day Moving Average 0.0
50-Day Moving Average 13.7262
20-Day Moving Average 10.6255
10-Day Moving Average 8.289
Average True Range 1.1737
ADX 39.69
+DI 10.7451
-DI 31.724
Chandelier Exit (Long, 3 ATRs ) 14.5439
Chandelier Exit (Short, 3 ATRs ) 10.9911
Upper Bollinger Band 17.2076
Lower Bollinger Band 4.0434
Percent B (%b) 0.3
BandWidth 123.892523
MACD Line -1.9562
MACD Signal Line -1.8927
MACD Histogram -0.0635
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 8.49
Resistance 3 (R3) 8.48 8.29 8.41
Resistance 2 (R2) 8.29 8.16 8.30 8.38
Resistance 1 (R1) 8.14 8.08 8.22 8.15 8.35
Pivot Point 7.95 7.95 7.99 7.96 7.95
Support 1 (S1) 7.80 7.82 7.88 7.81 7.61
Support 2 (S2) 7.61 7.74 7.62 7.58
Support 3 (S3) 7.46 7.61 7.56
Support 4 (S4) 7.47